Rush Medical Center Home Page Information for healthcare Professionals Rush University
FIND A DOCTOR
PATIENT & VISTOR SERVICES
HEALTH INFORMATION
CLINICAL SERVICES
EVENTS & CLASSES
RUSH NEWS ROOM
CLINICAL TRIALS
RESEARCH AT RUSH
NURSING AT RUSH
WORK AT RUSH
GIVING TO RUSH

Bookmark This Page
Clinical Trails at Rush Anti-Amyloid Treatment in Asymptomatic Alzheimers
Clinical Trial Protocol ID
13111101

Clinical Trial Investigator Name
Neelum Aggarwal

Clinical Trial Title

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease



Clinical Trial Protocol Description

The purpose of this 3-year study is to test the hypothesis that solanezumab will slow the decline of perceived cognitive functions and performance of everyday activities, as compared with placebo, in persons with preclinical Alzheimer’s disease.

Subjects will receive intravenous infusions of blinded study treatment every 4 weeks. Subjects will undergo MRI and PET scans, and an optional LP, cognitive and physical function testing, ECGs and blood draws throughout the course of the study. Clinic visits every 12 weeks will be conducted.

At Rush, we expect to recruit approximately 10 patients. The treatment will be assigned randomly.



Clinical Trial Eligibility Criteria
In order to participate you must have:
  • Are 65-85 years of age
  • Have a reliable study partner
You will be excluded from the study if  you:
  • Have serious or unstable illnesses, or do not have good venous access
  • Cannot undergo MRI, PET or lumbar puncture procedures

This is a partial list of inclusion and exclusion criteria.





Contact Name Lindsay Pluff
Contact Phone 312-563-4111
Promotional Information

Clinical Trials Home
Alzheimer's Disease Trials
Anti-Amyloid Treatment in Asymptomatic Alzheimers

   
Find a Doctor | Patient & Visitor Services | Health Information
Clinical Services | Events & Classes | Rush News Room | Clinical Trials
Research At Rush
Disclaimer | Privacy Statement | Site Map

© Rush University Medical Center, Chicago, Illinois